Articles tagged with Chemotherapy
A new case study using 5 head and neck squamous cell carcinoma cell lines shows improved drug screening through morphology and dead cell readouts. The research aims to enhance the value of cancer drug discovery and development success rates.
A recent study found that older cancer patients taking 15 or more medications prior to chemotherapy treatment had a 114% increase in hospitalization rates. The researchers also identified similar increases in breast and prostate cancer patients, with median medication counts of 6, 10, and 11 therapies respectively.
Combining therapeutic HPV vaccine ISA101 with chemotherapy drugs carboplatin and paclitaxel may extend survival in patients with advanced cervical cancer. The vaccine was well-tolerated, reducing suppressive myeloid cells to better stimulate T cell responses.
Researchers developed a microRNA-based signature that predicts local-regional failure and overall survival in patients with pancreatic cancer. The four-miRNA risk score provides prognostic information for clinical outcomes after surgical resection.
Researchers found that pairing Abraxane with Intralipid enhances tumor-killing macrophages, reducing cancer growth and protecting organs from damage. The combination also decreases the amount of expensive drugs needed for treatment.
A new imaging technique allows researchers to study 3D printed brain tumors in unprecedented detail, revealing how treatments affect complex tumor cells. This method provides a more accurate evaluation of drug effectiveness than traditional methods, which could lead to improved treatment outcomes for patients with glioblastomas.
A new trial has found that chemotherapy after surgery significantly reduces the risk of rare kidney cancer returning. The treatment has been shown to increase survival rates by over half, with 71% of patients living cancer-free for three years or more.
Yong Lu and David Soto-Pantoja receive grants to study immunotherapy and cardiotoxicity, aiming to improve cancer treatment outcomes and prevent heart disease. Their research could lead to new approaches in combating metastatic and treatment-resistant cancers.
Researchers at CNIO propose a novel approach using CDK4/6 inhibitors after chemotherapy to prevent tumor cells from resisting treatments. This strategy shows promising results in preventing tumor growth and death in mice with pancreatic adenocarcinoma, suggesting new avenues for improving cancer treatment.
The study found that patients whose breast cancer was completely eradicated by chemotherapy had a higher proportion of DNA mutational 'signature 3', indicating defects in DNA repair. This signature is associated with genes like BRCA, which could help doctors predict patient response to neoadjuvant chemotherapy.
A team of NUS researchers identified a novel protein S1P2 that can protect nerve cells from damage and pain when activated with a drug-like compound. This discovery holds promise for the prevention and treatment of chemotherapy-induced neuropathy, as well as other forms of neuropathy.
Researchers at Hackensack Meridian Health's CDI laboratory have made a breakthrough in treating blood cancers, specifically leukemia. They identified a novel protein called Stem Cell Growth Factor Alpha (SCGFa), which has shown promise in preserving vascular function and promoting hematopoietic recovery following chemotherapy.
Researchers at KAIST have discovered mechanisms that fuel a 'domino effect' in cancer drug resistance, enabling failed responses to paclitaxel to speed up the evolution of resistance to other drugs. The study suggests a new strategy for improving second-line cancer treatment.
A type of micro RNA known as MIR1249 plays a key role in allowing bile duct cancers to resist chemotherapy. The researchers hope that targeting this molecule could make chemotherapy more effective.
Professor Lillian Siu receives TAT 2020 Honorary Award for her contributions to early drug development and phase I trials in head and neck malignancies. She advances the field of cancer drug development with innovative clinical trial designs and methodologies.
Researchers at Mayo Clinic have discovered a method to make tumor cells more responsive to immunotherapy. By promoting genetic mutations in tumor cells, they found that these cells become vulnerable to immune system attacks. The approach showed promise across different types of tumors and patient genomes.
A University of Colorado Cancer Center study found that patients with locally advanced rectal cancer who received lower-than-recommended doses of neoadjuvant chemotherapy experienced a complete response and tumor shrinkage similar to those receiving the full dose.
A pilot study conducted by INRS researchers highlights the effect of chemotherapy on male fertility before and after puberty. The study found that all patients were at higher risk of infertility due to low sperm production, regardless of age at diagnosis.
A study by the Broad Institute of MIT and Harvard uncovered nearly 50 non-oncology drugs that can kill cancer cells, including those for diabetes, inflammation, and arthritis. The researchers identified novel drug mechanisms and targets, suggesting a possible way to accelerate the development of new cancer drugs.
Researchers developed a novel cryogel vaccine that primes the immune system to attack and eliminate acute myeloid leukemia cells in mice. The vaccine successfully protected against disease recurrence when combined with chemotherapy.
A new clinical trial has shown that giving men one cycle of chemotherapy is as effective at preventing testicular cancer from coming back as two cycles. This reduction in chemotherapy dosage lowered debilitating side effects, improving patients' quality of life.
Researchers at IKBFU identified spirocycles as a building block of organic molecules with potential for medical chemistry development. These naturally occurring compounds, such as artemisinin, exhibit biocompatibility and have inspired the synthesis of new medicinal compounds.
A Mayo Clinic study of 5,540 patients with metastatic colorectal cancer found that maintenance chemotherapy after initial treatment is more beneficial for patients whose disease is under control. The preferred regimen is fluoropyrimidine with or without bevacizumab, according to the analysis.
A new study led by Christine B. Ambrosone found that breast cancer patients taking antioxidants during chemotherapy had a 41% increased risk of disease recurrence and a similar but weaker risk of death. Patients using vitamin B12, iron, and omega-3 fatty acid supplements also showed poorer outcomes.
A metabolic inhibitor called OSI-027 induces catastrophic macropinocytosis in human cancer cells, reducing tumor growth when combined with chemotherapy. The study suggests that targeting the mTOR pathway may be an effective approach to treat drug-resistant cancers.
Researchers found that women who used ibuprofen or naproxen had a 40% reduced breast cancer risk, while aspirin use offered no benefit. Young women with HER2-positive breast cancer may preserve fertility by choosing less intensive chemotherapy regimens.
Salk researchers found that mitochondria trigger molecular alarms when cells are stressed, which can lead to increased resistance to chemotherapy. This discovery may pave the way for new cancer treatments that target mitochondrial stress.
Blinatumomab treatment demonstrates longer survival, fewer severe side effects, and higher undetectable residual disease rates compared to standard chemotherapy for children with high- or intermediate-risk B-cell acute lymphoblastic leukemia. The study shows promising results as a bridge to curative bone marrow transplant.
A new combination therapy of lower-dose chemotherapy and monoclonal antibodies has shown a 98% response rate in older patients with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia. The three-year survival rate was 54%, with 30 patients in complete remission without signs of minimal residual disease.
A study by Dana-Farber researchers suggests that adding venetoclax to a reduced-intensity drug regimen prior to stem cell transplant can increase the chances of transplant success. The treatment has been found to be safe and does not impair donor cells' ability to engraft in recipients.
Researchers at the University of Cincinnati developed a new treatment for glioblastoma multiforme using coaxial electrospinning, which delivers a potent dose of medicine immediately or over time. The treatment improved survival rates in three separate animal trials and holds promise for other types of cancer.
A study published in SPIE Journal of Biomedical Optics found that diffuse reflectance spectroscopy can reliably discriminate between healthy tissue and tumor tissue, regardless of neoadjuvant chemotherapy status. The technique's feasibility for tumor-margin assessment during breast-conserving surgery has been demonstrated.
Researchers have created a new technique to deliver chemotherapy directly to malignant cells, bypassing healthy ones. This discovery could allow doctors to reduce chemo doses and alleviate side effects, improving treatment outcomes.
The study found that API-5 is overexpressed in chemoresistant TNBC, associated with increased micro-vessel density and enhanced cell survival. A peptide targeting API-5 shows promise as an innovative treatment option for this aggressive cancer type.
Researchers have developed 'combo' nanoplatforms using graphene oxide and reduced graphene oxide to enhance chemotherapy therapy. These nanocarriers can target tumors and improve drug delivery, reducing side effects on normal cells/tissues.
Scientists have characterised genetic alterations caused by six cancer therapies, revealing 'mutational footprints' that can help optimize treatment efficacy and minimize side effects. The study provides a new understanding of the relationship between therapy-induced mutations and long-term side effects.
Researchers discovered that SNAP, a nitric oxide donor, overcomes TMZ resistance in glioblastoma multiforme (GBM) cells by reducing MGMT protein stability. This finding offers a potential strategy to improve treatment outcomes for patients with GBM.
Researchers found that API-5 was overexpressed in endothelial cells of patients with chemoresistant TNBC, associated with increased micro-vessel density. API-5 promotes cell survival and cancer growth by inhibiting apoptosis.
A new technique called ELeCt uses drug-loaded nanoparticles bound to circulating red blood cells to inhibit lung cancer metastasis with tenfold greater success than free-floating nanoparticles. The research has shown improved survival rates and reduced side effects in mice with lung cancer, making it a promising clinical treatment.
Researchers at the University of Texas MD Anderson Cancer Center found that secondary tumor-reduction surgery followed by chemotherapy did not result in longer survival than chemotherapy alone. The study involved 240 patients with platinum-sensitive recurrent ovarian cancer and showed that complete tumor resection was associated with i...
A study in mice shows that chemotherapy affects gut bacteria, inflammation, and cognitive problems. Researchers found correlations between changes in the gut microbiome and brain inflammation, which could lead to new interventions for cancer patients.
Most UK mastectomies are advised for large tumours; standard hormone therapy and chemotherapy could reduce number of women needing surgery.
A new study by Cincinnati Children's Hospital Medical Center suggests that the drug bortezomib may help re-balance disrupted muscle growth and prevent muscle contractures in children with brachial plexus injury or cerebral palsy. The treatment shows promise in preventing loss of elbow and shoulder motion and disrupting skeletal growth.
Gabapentinoid prescriptions for adults with cancer grew from 3.3% to 8.3% between 2005 and 2015, with total prescriptions increasing from 1.2 million to 3.5 million. Further study is needed to understand the effectiveness and risks of gabapentinoids in treating cancer pain.
Researchers discovered that Pixantrone interacts with cancer DNA by prising apart the double helix structure and compacting its backbone. This mechanism could lead to the development of more effective cancer drugs with reduced harm to healthy cells.
Electrospun fibers are being explored as a novel method for creating effective contraceptives and treating brain tumors. A University of Cincinnati study discovered that coaxial electrospinning can combine different materials to improve drug delivery and effectiveness.
A novel methodology was developed to extract data on symptoms from EHRs and investigate associations between symptom clusters and disease. The study identified distinct symptom clusters for breast cancer and colorectal cancer patients, providing critical information for patient care teams and researchers.
A compound has been identified as effective in killing chemotherapy-resistant glioblastoma-initiating cells (GICs), a major challenge in treating this devastating cancer. The research also showed that the compound is non-toxic to normal cells, raising hopes for developing drugs with low toxicity.
Researchers created a test using tumor organoids to predict how patients with advanced colorectal cancer respond to chemotherapy treatment. The test correctly classified 80% of patients treated with irinotecan, suggesting it could help identify those who won't benefit from toxic chemotherapies.
A new analysis published in Annals of Oncology suggests that hormone therapy has a greater impact on women's quality of life compared to chemotherapy, especially in postmenopausal patients. This finding challenges current international guidelines recommending prolonged hormone therapy for 5-10 years.
A University of South Florida researcher is studying whether a home-based exercise program can decrease the severity of nerve and muscle symptoms from chemotherapy-induced peripheral neuropathy in breast cancer survivors. The study aims to provide an evidence-based intervention for patients suffering from persistent neuropathy.
A recent study presented at the ESMO Congress 2019 found that nearly four times more patients responded to immunotherapy with pembrolizumab than standard chemotherapy in a trial for advanced mesothelioma. However, these responses did not delay progression or improve survival rates.
The TAILORx trial has shown that women with high Recurrence Scores (26-100) have a 93% chance of being cancer-free after five years, with those receiving chemotherapy having a significantly better outcome. The findings support the use of adjuvant chemotherapy to improve treatment outcomes in early breast cancer patients.
A new treatment using niraparib after conventional chemotherapy improves progression-free survival and reduces risk of relapse or death in patients with advanced ovarian cancer. The study, led by Dr. Antonio González Martín, found a significant reduction in risk of relapse, especially in patients with homologous recombination deficiency.
The CheckMate-227 trial found that the combination of nivolumab and low-dose ipilimumab improves overall survival in patients with advanced non-small cell lung cancer compared to chemotherapy. The treatment was well-tolerated, with a low rate of discontinuation and treatment-related toxicities.
A Phase III trial validates the benefit of veliparib for patients with newly diagnosed, metastatic high-grade serous ovarian cancer. The combination therapy achieved a PFS of 23.5 months, compared to 17.3 months for the control arm.
A new nanotechnology-based process uses magnetic particle imaging to monitor chemotherapy concentrations in real-time, allowing doctors to adjust doses precisely. This innovation has the potential to minimize side effects and improve treatment outcomes for cancer patients.
Researchers at the Buck Institute identified 44 specific senescence-associated proteins involved in blood clotting, marking the first time cellular senescence has been associated with age-related blood clots. Senescent cells accumulate over time, spewing out inflammatory proteins that lead to chronic inflammation.
Researchers discovered the mechanism behind cetuximab's effectiveness in patients with a specific KRAS gene mutation, which enables doctors to prescribe the drug to this patient group. This finding has direct clinical implications and could benefit up to 10,000 colorectal cancer patients per year.
Researchers at Johns Hopkins Medicine developed a compound that extends survival in mice models of pediatric brain tumors, particularly those expressing the MYC oncogene. The compound inhibits glutamine metabolism, making chemotherapy more effective.